잠시만 기다려 주세요. 로딩중입니다.

Effects of probiotics or broccoli supplementation on Helicobacter pylori eradication with standard clarithromycin-based triple therapy

Korean Journal of Internal Medicine 2020년 35권 3호 p.574 ~ 581
장영운, 박유민, Oh Chi-Hyuk, Oh Shin-Ju, 조준형, 김정욱, 장재영,
소속 상세정보
장영운 ( Chang Young-Woon ) - Kyung Hee University College of Medicine Department of Internal Medicine
박유민 ( Park Yoo-Min ) - Kyung Hee University College of Medicine Department of Internal Medicine
 ( Oh Chi-Hyuk ) - Kyung Hee University College of Medicine Department of Internal Medicine
 ( Oh Shin-Ju ) - Kyung Hee University College of Medicine Department of Internal Medicine
조준형 ( Cho Jun-Hyung ) - Soonchunhyang University College of Medicine Department of Internal Medicine
김정욱 ( Kim Jung-Wook ) - Kyung Hee University College of Medicine Department of Internal Medicine
장재영 ( Jang Jae-Young ) - Kyung Hee University College of Medicine Department of Internal Medicine

Abstract


Background/Aims: The eradication failure rate of standard triple therapy (proton pump inhibitor, clarithromycin, and amoxicillin) for Helicobacter pylori infection has increased owing to antibiotic resistance in Korea. We assessed whether Saccharomyces boulardii probiotic or broccoli sprout extract sulforaphane supplementation could increase the H. pylori eradication rate and/or reduce antibiotic-associated adverse events.

Methods: A total of 217 patients with H. pylori-positive chronic gastritis or peptic ulcer disease were recruited. Clarithromycin resistance was assessed in all patients by testing for A2142G and A2143G point mutations in H. pylori 23S rRNA using a dual-priming polymerase chain reaction (PCR) oligonucleotide. Thirty-four patients (17.3%) were clarithromycin-resistant and were excluded from the study. Finally, 183 patients with infections not resistant to clarithromycin were randomly assigned to triple therapy only (group A, n = 61), triple therapy plus probiotics (group B, n = 61), or triple therapy plus sulforaphane (group C, n = 61) groups. CYP2C19 polymorphisms were examined at position G681A of exon 5 and G636A of exon 4 by PCR with restriction fragment length polymorphism (PCR-RFLP) analysis. H. pylori eradication was assessed by 13C-urea breath test 4 weeks after treatment completion.

Results: The eradication rates were similar among the groups both in the intention-to-treat (A = 85.2%, B = 89.6%, and C = 81.6%) and per-protocol (A = 89.2%, B = 86.8%, and C = 96.3%) analyses. The frequencies of overall adverse events in the groups also did not differ (A vs. B: p = 0.574; A vs. C: p = 1.000).

Conclusions: Probiotic or sulforaphane with triple therapy for H. pylori infection neither increased the eradication rate nor reduced the occurrence of adverse events.

키워드

Helicobacter pylori; Probiotics; Sulforaphane

원문 및 링크아웃 정보

  

등재저널 정보